Summary & Overview
HCPCS J2801: Risperidone (Rykindo) Injection, 0.5 mg
HCPCS Level II code J2801 denotes the administration of risperidone (Rykindo) in 0.5 mg units as a long-acting injectable antipsychotic. Nationally, accurate coding for long-acting injectables matters for clinical continuity, payer coverage determinations, and outpatient behavioral health delivery. The code is used where injectable risperidone is provided in ambulatory settings and physician offices.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the medication, typical sites of service, and the billing code’s role in claims processing. The publication also summarizes common modifiers and administrative notes associated with J2801, national payer coverage patterns, and benchmark metrics where available.
This summary provides clinicians, billing staff, and policy analysts with practical context on code application, payer considerations, and what to expect in claims workflows for long-acting risperidone injections.
Billing Code Overview
HCPCS Level II code J2801 represents an injection of risperidone (Rykindo), 0.5 mg. This code describes the administration of a long-acting injectable antipsychotic formulation of risperidone measured in 0.5 mg increments.
-
Service type: Medication injection (long-acting antipsychotic)
-
Typical site of service: Ambulatory clinics, outpatient behavioral health centers, and physician offices where injectable psychotropic medications are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 28-year-old outpatient with a diagnosis of schizophrenia stabilized on oral risperidone presents for scheduled long-acting injectable risperidone therapy. The patient arrives at an ambulatory behavioral health clinic staffed by a psychiatrist and nursing staff. After verification of identity, allergies, and recent medication history, a registered nurse reviews injection consent and screens for contraindications such as recent hypersensitivity reactions or active neuroleptic malignant syndrome. The nurse inspects the deltoid and gluteal sites for infection or trauma, selects the appropriate syringe and needle, and prepares the J2801 risperidone injection (0.5 mg units as billed per 0.5 mg). The medication is administered intramuscularly (typically deltoid or gluteal) with post-injection observation for 15–30 minutes for adverse effects (extrapyramidal symptoms, orthostatic hypotension, sedation). Documentation includes medication lot number, dose administered, site of injection, patient tolerance, and any counseling provided. Billing uses J2801 units corresponding to the milligram amount administered. Typical sites of service include ambulatory infusion centers, outpatient behavioral health clinics, psychiatric hospitals, and skilled nursing facilities when long-acting injectable antipsychotic therapy is delivered by credentialed nursing staff.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |